Cyclosporine induced biochemical remission in childhood autoimmune hepatitis
- PMID: 23213960
Cyclosporine induced biochemical remission in childhood autoimmune hepatitis
Abstract
The conventional treatment of autoimmune hepatitis (AIH) in children, which includes prednisone alone or in combination with azathioprine, induces remission in most cases but is often associated with poorly tolerated side effects. To avoid the adverse effects, Alvarez et al. introduced an alternative treatment regimen, using cyclosporine A (CyA) as primary immunosuppression. We carried out a retrospective study to evaluate the efficacy and tolerance of CyA treatment in children and adolescents with AIH treated in our center. During 2000-2010 period, nine children (6 female) aged 5-17.5 years, were diagnosed with AIH according to established international criteria. Following the suggested protocol, CyA was administered orally and when the transaminases tended to normalise, dose was adjusted to lover serum levels. Conversion to low dose of prednisone and azathioprine was started after 6 months, with gradual tapering and discontinuation of CyA. All nine patient had elevated transaminases and gammaglobulin levels, with proven histological changes typical for AIH in 8 patients that underwent liver biopsy (in one patient biopsy was contraindicated due to the prolonged prothrombin time). Serum ANA/SMA autoantibodies were positive in all but one patient, who had positive anti-LKM1. Complete or near complete and persistent normalisation of transaminase activity was observed in 8/9 patients within first 6 to 12 months. In one patient with partial response, an overlap syndrome was established. After ursodeoxycholic acid was added complete remission was observed. All patients had excellent clinical course and histological improvement. During the long-term follow-up (1.5-9 yrs; median 4.5 yrs), biochemical relapse occured in one patient after discontinuation of maintenance corticosteroid dose. Despite registered improvement, none of the patients fulfilled the criteria for therapy discontinuation, so all of them are still receiving maintenance doses of prednisone or azathioprine. The applied protocol allowed for the control of the liver inflammatory disease in all of our patients and protected them from the side effects related to steroid treatment. Side effects of CyA were minimal and were well tolerated.
Similar articles
-
Long-term management and prognosis of autoimmune hepatitis (AIH): a single center experience.Z Gastroenterol. 2001 May;39(5):339-41, 344-8. doi: 10.1055/s-2001-13708. Z Gastroenterol. 2001. PMID: 11413913
-
Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents.J Pediatr. 2013 Nov;163(5):1347-53.e1. doi: 10.1016/j.jpeds.2013.05.042. Epub 2013 Jun 28. J Pediatr. 2013. PMID: 23810723 Clinical Trial.
-
Short-term cyclosporine induces a remission of autoimmune hepatitis in children.J Hepatol. 1999 Feb;30(2):222-7. doi: 10.1016/s0168-8278(99)80065-8. J Hepatol. 1999. PMID: 10068099 Clinical Trial.
-
Therapeutic strategies for autoimmune hepatitis.Dig Dis. 2011;29(4):411-5. doi: 10.1159/000329805. Epub 2011 Aug 30. Dig Dis. 2011. PMID: 21894012 Review.
-
Autoimmune diseases of the liver and biliary tract and overlap syndromes in childhood.Minerva Gastroenterol Dietol. 2009 Mar;55(1):53-70. Minerva Gastroenterol Dietol. 2009. PMID: 19212308 Review.
Cited by
-
Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments.World J Gastroenterol. 2017 Sep 7;23(33):6030-6048. doi: 10.3748/wjg.v23.i33.6030. World J Gastroenterol. 2017. PMID: 28970719 Free PMC article.